{"a":[{"_":"Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate","$":{"href":"/pharma/akeso-ceo-looks-beyond-lung-cancer-phase-3-biliary-tract-win-counters-ivonescimab-debate","hreflang":"en"}}]}

Phase 3positiveivonescimabPositive

AI Analysis

Summary

Akeso announced a phase 3 win for ivonescimab in biliary tract cancer, demonstrating the PD-1xVEGF bispecific antibody's potential beyond its non-small cell lung cancer indication. CEO Michelle Xia is defending the drug's data amid ongoing skepticism regarding its efficacy.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Phase 3 win in biliary tract cancer

Importance:7/10

Sentiment:

0.65

phase 3 databiliary tract cancerPD-1xVEGF bispecific antibodyoncologylung cancer expansion

Read the original article

Published by FiercePharma on August 26, 2026 10:48 AM

Read Original